Eli Lilly (LLY)

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.

There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival.

Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.

Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?

Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.

Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% chance of closing higher.

Eli Lilly to acquire SiteOne Therapeutics in a deal worth up to $1 billion, advancing the development of a potential non-opioid treatment for chronic pain.

Adjusted net profit jumped 64.5% YoY to hit a record high of RMB10.7 billion during the quarter.

President Trump has good news for Novo Nordisk investors, and more may be on the way.

The $1 billion is inclusive of an upfront payment and subsequent payments upon achievement of certain regulatory and commercial milestones.